Q. Is ONXOL™ (paclitaxel) Injection a generic equivalent of TAXOL® ?
A.

Yes. In September of 2000, the Food and Drug Administration (FDA) approved
ONXOL™ as safe and effective for use as recommended in the product labeling and
gave the product an AP rating. For an injectable solution, like ONXOL™, an AP
rating indicates that the product is therapeutically equivalent to the brand
reference. FDA believes that products classified as therapeutically equivalent
can be substituted with the full expectation that the substituted product will
produce the same clinical effect and safety profile as the brand reference.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Q. Is the rubber stopper made from latex material?
A. The rubber stopper and product are made from non-latex materials.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Q. Is there a patient assistance program for ONXOL™?
A. Yes.
IVAX Oncology Assistance ProgramSM
phone: 1-866-489-5955
fax: 1-866-489-5953

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -


 
 
Copyright 2002 IVAX Corp. All rights reserved. Legal Disclaimer and Privacy Policy.
The health information contained herein is provided for educational purposes only and is not intended to replace discussions with a healthcare
provider. All decisions regarding patient care must be made with a healthcare provider, considering the unique characteristics of the patient.

This information is intended only for residents of the United States.
ONXOL™ is a trademark of IVAX Research, Inc.
TAXOL® is a registered trademark of BRISTOL-MYERS SQUIBB CO.
0302-03-M